531
Views
13
CrossRef citations to date
0
Altmetric
Special Review Series

Novel scientific approaches and future research directions in understanding ITP

ORCID Icon, ORCID Icon, , ORCID Icon & ORCID Icon
Pages 315-321 | Received 04 Feb 2020, Accepted 06 Feb 2020, Published online: 13 Feb 2020

References

  • Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386–2393.
  • Neunert CE. Management of newly diagnosed immune thrombocytopenia: can we change outcomes? Blood Adv 2017;1:2295–2301.
  • Arnold DM, Nazy I, Clare R, Jaffer AM, Aubie B, Li N, Kelton JG. Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry. Blood Adv 2017;1:2414–2420.
  • Chong BH, Choi PY, Khachigian L, Perdomo J. Drug-induced immune thrombocytopenia. Hematol Oncol Clin North Am 2013;27:521–540.
  • Zufferey A, Kapur R, Semple JW. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). J Clin Med 2017;6:16.
  • McMillan R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin Hematol 2000;37:239–248.
  • He R, Reid DM, Jones CE, Shulman NR. Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. Blood 1994;83:1024–1032.
  • Vollenberg R, Jouni R, Norris PAA, Burg-Roderfeld M, Cooper N, Rummel MJ, Bein G, Marini I, Bayat B, Burack R, et al. Glycoprotein V is a relevant immune target in patients with immune thrombocytopenia. Haematologica 2019;104:1237–1243.
  • Rabbolini DJ, Gardiner EE, Morel-Kopp M-C, Dunkley S, Jahangiri A, Lee CSM, Stevenson WS, Ward CM. Anti-glycoprotein VI mediated immune thrombocytopenia: an under-recognized and significant entity? Res Prac Thromb Haemost 2017;1:291–295.
  • Gardiner EE, Al-Tamimi M, Mu FT, Karunakaran D, Thom JY, Moroi M, Andrews RK, Berndt MC, Baker RI. Compromised ITAM-based platelet receptor function in a patient with immune thrombocytopenic purpura. J Thromb Haemost 2008;6:1175–1182.
  • Hiyoyama K, Wada H, Shimura M, Nakasaki T, Katayama N, Nishikawa M, Shiku H, Tahara T, Kato T. Increased serum levels of thrombopoietin in patients with thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura, or disseminated intravascular coagulation. Blood Coagul Fibrinolysis 1997;8:345–349.
  • Al-Samkari H, Kuter DJ. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia. Am J Hematol 2018;93:1501–1508.
  • Audia S, Mahevas M, Samson M, Godeau B, Bonnotte B. Pathogenesis of immune thrombocytopenia. Autoimmun Rev 2017;16:620–632.
  • Olsson B, Andersson PO, Jernas M, Jacobsson S, Carlsson B, Carlsson LM, Wadenvik H. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003;9:1123–1124.
  • Li S, Wang L, Zhao C, Li L, Peng J, Hou M. CD8+ T cells suppress autologous megakaryocyte apoptosis in idiopathic thrombocytopenic purpura. Br J Haematol 2007;139:605–611.
  • Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood 2017;129:2829–2835.
  • Swain F, Bird R. How I approach new onset thrombocytopenia. Platelets 2019. in press.
  • Greinacher A, Pecci A, Kunishima S, Althaus K, Nurden P, Balduini CL, Bakchoul T. Diagnosis of inherited platelet disorders on a blood smear: a tool to facilitate worldwide diagnosis of platelet disorders. J Thromb Haemost 2017;15:1511–1521.
  • Noris P, Biino G, Pecci A, Civaschi E, Savoia A, Seri M, Melazzini F, Loffredo G, Russo G, Bozzi V, et al. Platelet diameters in inherited thrombocytopenias: analysis of 376 patients with all known disorders. Blood 2014;124:e4–e10.
  • Lamy T, Moisan A, Dauriac C, Ghandour C, Morice P, Le Prise PY. Splenectomy in idiopathic thrombocytopenic purpura: its correlation with the sequestration of autologous indium-111-labeled platelets. J Nucl Med 1993;34:182–186.
  • Roca M, Muniz-Diaz E, Mora J, Romero-Zayas I, Ramon O, Roig I, Pujol-Moix N. The scintigraphic index spleen/liver at 30 minutes predicts the success of splenectomy in persistent and chronic primary immune thrombocytopenia. Am J Hematol 2011;86:909–913.
  • Sarpatwari A, Provan D, Erqou S, Sobnack R, David Tai FW, Newland AC (2010) Autologous 111 In-labelled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: a report from the United Kingdom ITP Registry. Br J Haematol 151, 477–487.
  • Siegel RS, Rae JL, Barth S, Coleman RE, Reba RC, Kurlander R, Rosse WF. Platelet survival and turnover: important factors in predicting response to splenectomy in immune thrombocytopenic purpura. Am J Hematol 1989;30:206–212.
  • McMillan R, Wang L, Tani P. Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP). J Thromb Haemost 2003;1:485–491.
  • He R, Reid D, Jones C, Shulman N. Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. Blood 1994;83:1024–1032.
  • Zeng Q, Zhu L, Tao L, Bao J, Yang M, Simpson EK, Li C, van der Wal DE, Chen P, Spring CM, et al. Relative efficacy of steroid therapy in immune thrombocytopenia mediated by anti-platelet GPIIbIIIa versus GPIbalpha antibodies. Am J Hematol 2012;87:206–208.
  • Li J, van der Wal DE, Zhu G, Xu M, Yougbare I, Ma L, Vadasz B, Carrim N, Grozovsky R, Ruan M, et al. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nat Commun 2015;6:e7737.
  • Grimaldi D, Canoui-Poitrine F, Croisille L, Lee K, Roudot-Thoraval F, Languille L, Khellaf M, Michel M, Godeau B, Bierling P. Antiplatelet antibodies detected by the MAIPA assay in newly diagnosed immune thrombocytopenia are associated with chronic outcome and higher risk of bleeding. Ann Hematol 2014;93:309–315.
  • Shao L, Wu Y, Zhou H, Qin P, Ni H, Peng J, Hou M. Successful treatment with oseltamivir phosphate in a patient with chronic immune thrombocytopenia positive for anti-GPIb/IX autoantibody. Platelets 2015;26:495–497.
  • Revilla N, Corral J, Miñano A, Mingot-Castellano ME, Campos RM, Velasco F, Gonzalez N, Galvez E, Berrueco R, Fuentes I, et al. Multirefractory primary immune thrombocytopenia; targeting the decreased sialic acid content. Platelets 2019;30:743–751.
  • Marini I, Zlamal J, Faul C, Holzer U, Hammer S, Pelzl L, Bethge W, Althaus K, Bakchoul T. Autoantibody-mediated desialylation impairs human thrombopoiesis and platelet life span. Haematologica 2019.
  • Kiefel V. The MAIPA assay and its applications in immunohaematology. Transf Med 1992;2:181–188.
  • Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168–186.
  • Brighton TA, Evans S, Castaldi PA, Chesterman CN, Chong BH. Prospective evaluation of the clinical usefulness of an antigen- specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood 1996;88:194–201.
  • Robinson M, MacHin S, Mackie I, Harrison P. In vivo biotinylation studies: specificity of labelling of reticulated platelets by thiazole orange and mepacrine. Br J Haematol 2000;108:859–864.
  • Denis MM, Tolley ND, Bunting M, Schwertz H, Jiang H, Lindemann S, Yost CC, Rubner FJ, Albertine KH, Swoboda KJ, et al. Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell 2005;122:379–391.
  • Nassa G, Giurato G, Cimmino G, Rizzo F, Ravo M, Salvati A, Nyman TA, Zhu Y, Vesterlund M, Lehtio J, et al. Splicing of platelet resident pre-mRNAs upon activation by physiological stimuli results in functionally relevant proteome modifications. Sci Rep 2018;8:498.
  • Barsam SJ, Psaila B, Forestier M, Page LK, Sloane PA, Geyer JT, Villarica GO, Ruisi MM, Gernsheimer TB, Beer JH, et al. Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia (ITP). Blood 2011;117:5723–5732.
  • Ferreira FLB, Colella MP, Medina SS, Costa-Lima C, Fiusa MML, Costa LNG, Orsi FA, Annichino-Bizzacchi JM, Fertrin KY, Gilberti MFP, et al. Evaluation of the immature platelet fraction contribute to the differential diagnosis of hereditary, immune and other acquired thrombocytopenias. Sci Rep 2017;7:3355.
  • Estcourt LJ, Stanworth SJ, Harrison P, Powter G, McClure M, Murphy MF, Mumford AD. Prospective observational cohort study of the association between thromboelastometry, coagulation and platelet parameters and bleeding in patients with haematological malignancies- the ATHENA study. Br J Haematol 2014;166:581–591.
  • Hoffmann JJ. Reticulated platelets: analytical aspects and clinical utility. Clin Chem Lab Med 2014;52:1107–1117.
  • Ibrahim H, Nadipalli S, Usmani S, DeLao T, Green L, Kleiman NS. Detection and quantification of circulating immature platelets: agreement between flow cytometric and automated detection. J Thromb Thrombolysis 2016;42:77–83.
  • Angenieux C, Dupuis A, Gachet C, de la Salle H, Maitre B. Cell surface expression of HLA I molecules as a marker of young platelets. J Thromb Haemost 2019;17:1511–1521.
  • Pavenski K, Freedman J, Semple JW. HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management. Tissue Antigens 2012;79:237–245.
  • Rowley JW, Oler AJ, Tolley ND, Hunter BN, Low EN, Nix DA, Yost CC, Zimmerman GA, Weyrich AS. Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes. Blood 2011;118:e101–e111.
  • Greinacher A. Heparin-induced thrombocytopenia. J Thromb Haemost 2009;7(Suppl 1):9–12.
  • Nurden P, Tandon N, Takizawa H, Couzi L, Morel D, Fiore M, Pillois X, Loyau S, Jandrot-Perrus M, Nurden AT. An acquired inhibitor to the GPVI platelet collagen receptor in a patient with lupus nephritis. J Thromb Haemost 2009;7:1541–1549.
  • Gardiner EE, Thom JY, Al-Tamimi M, Hughes A, Berndt MC, Andrews RK, Baker RI. Restored platelet function after romiplostim treatment in a patient with immune thrombocytopenic purpura. Brit J Haematol 2010;149:625–628.
  • Moroi M, Jung SM, Okuma M, Shinmyozu K. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest 1989;84:1440–1445.
  • Coller BS, Kalomiris E, Steinberg M, Scudder LE. Evidence that glycocalicin circulates in normal plasma. J Clin Invest 1984;73:794–799.
  • Khaspekova SG, Shustova ON, Golubeva NV, Vasiliev SA, Mazurov AV. Relationships of mean platelet volume and plasma thrombopoietin with glycocalicin levels in thrombocytopenic patients. Acta Haematol 2015;133:295–299.
  • Forestier M, Al-Tamimi M, Gardiner EE, Hermann C, Meyer SC, Beer JH. Diesel exhaust particles impair platelet response to collagen and are associated with GPIbα shedding. Toxicol In Vitro 2012;26:930–938.
  • Urbanus RT, van der Wal DE, Koekman CA, Huisman A, van den Heuvel DJ, Gerritsen HC, Deckmyn H, Akkerman J-WN, Schutgens REG, Gitz E. Patient autoantibodies induce platelet destruction signals via raft-associated glycoprotein Ibα and FcγRIIa in immune thrombocytopenia. Haematologica 2013;98:e70–e72.
  • van der Wal DE, Davis AM, Mach M, Marks DC. The role of neuraminidase 1 and 2 in glycoprotein Ibα-mediated integrin αIIbβ3 activation. Haematologica 2019;e215830.
  • Grozovsky R, Giannini S, Falet H, Hoffmeister KM. Regulating billions of blood platelets: glycans and beyond. Blood 2015;126:1877–1884.
  • Webster ML, Sayeh E, Crow M, Chen P, Nieswandt B, Freedman J, Ni H. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbα antibodies. Blood 2006;108:943–946.
  • Greene LA, Chen S, Seery C, Imahiyerobo AM, Bussel JB. Beyond the platelet count: immature platelet fraction and thromboelastometry correlate with bleeding in patients with immune thrombocytopenia. Br J Haematol 2014;166:592–600.
  • Gunduz E, Akay OM, Bal C, Gulbas Z. Can thrombelastography be a new tool to assess bleeding risk in patients with idiopathic thrombocytopenic purpura? Platelets 2011;22:516–520.
  • Alvarez-Roman MT, Fernandez-Bello I, Jimenez-Yuste V, Martin-Salces M, Arias-Salgado EG, Rivas Pollmar MI, Justo Sanz R, Butta NV. Procoagulant profile in patients with immune thrombocytopenia. Br J Haematol 2016;175:925–934.
  • Opheim EN, Apelseth TO, Stanworth SJ, Eide GE, Hervig T. Thromboelastography may predict risk of grade 2 bleeding in thrombocytopenic patients. Vox Sang 2017;112:578–585.
  • Choi PY-I, Hicks S, Gardiner EE, Crispin P, Slade J, D’Rozario J, Parish C, Coupland L. Platelet dysfunction detected using rotational thromboelastometry (ROTEM) in severely thrombocytopenic patients with a bleeding phenotype. Blood 2019;134:2357.
  • Ji SM, Kim SH, Nam JS, Yun HJ, Choi JH, Lee EH, Choi IC. Predictive value of rotational thromboelastometry during cardiopulmonary bypass for thrombocytopenia and hypofibrinogenemia after weaning of cardiopulmonary bypass. Korean J Anesthesiol 2015;68:241–248.
  • Zwifelhofer NMJ, Bercovitz RS, Cole R, Yan K, Simpson PM, Moroi A, Newman PJ, Niebler RA, Scott JP, Stuth EAD, et al. Platelet function changes during neonatal cardiopulmonary bypass surgery: mechanistic basis and lack of correlation with excessive bleeding. Thromb Haemost 2020;120:94–106.
  • McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004;103:1364–1369.
  • Chang M, Nakagawa PA, Williams SA, Schwartz MR, Imfeld KL, Buzby JS, Nugent DJ. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003;102:887–895.
  • Houwerzijl EJ, Blom NR, van der Want JJ, Esselink MT, Koornstra JJ, Smit JW, Louwes H, Vellenga E, de Wolf JT. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 2004;103:500–506.
  • Olsson B, Ridell B, Carlsson L, Jacobsson S, Wadenvik H. Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. Blood 2008;112:1078–1084.
  • Perdomo J, Yan F, Chong BH. A megakaryocyte with no platelets: anti-platelet antibodies, apoptosis, and platelet production. Platelets 2013;24:98–106.
  • Seo H, Chen SJ, Hashimoto K, Endo H, Nishi Y, Ohta A, Yamamoto T, Hotta A, Sawaguchi A, Hayashi H, et al. A β1-tubulin-based megakaryocyte maturation reporter system identifies novel drugs that promote platelet production. Blood Adv 2018;2:2262–2272.
  • Iraqi M, Perdomo J, Yan F, Choi PY, Chong BH. Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro. Haematologica 2015;100:623–632.
  • Sakakura M, Wada H, Tawara I, Nobori T, Sugiyama T, Sagawa N, Shiku H. Reduced Cd4+Cd25+ T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res 2007;120:187–193.
  • Li X, Zhong H, Bao W, Boulad N, Evangelista J, Haider MA, Bussel J, Yazdanbakhsh K. Defective regulatory B-cell compartment in patients with immune thrombocytopenia. Blood 2012;120:3318–3325.
  • Audia S, Rossato M, Santegoets K, Spijkers S, Wichers C, Bekker C, Bloem A, Boon L, Flinsenberg T, Compeer E, et al. Splenic TFH expansion participates in B-cell differentiation and antiplatelet-antibody production during immune thrombocytopenia. Blood 2014;124:2858–2866.
  • Zhao C, Li X, Zhang F, Wang L, Peng J, Hou M. Increased cytotoxic T-lymphocyte-mediated cytotoxicity predominant in patients with idiopathic thrombocytopenic purpura without platelet autoantibodies. Haematologica 2008;93:1428–1430.
  • Chattopadhyay PK, Gierahn TM, Roederer M, Love JC. Single-cell technologies for monitoring immune systems. Nat Immunol 2014;15:128–135.
  • Blair TA, Frelinger AL 3rd. Platelet surface marker analysis by mass cytometry. Platelets 2019;1–8.
  • Bendall SC, Nolan GP, Roederer M, Chattopadhyay PK. A deep profiler’s guide to cytometry. Trends Immunol 2012;33:323–332.
  • Sanders CK, Mourant JR. Advantages of full spectrum flow cytometry. J Biomed Opt 2013;18:037004.
  • Salgame P, Abrams JS, Clayberger C, Goldstein H, Convit J, Modlin RL, Bloom BR. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 1991;254:279–282.
  • Toltl LJ, Nazi I, Jafari R, Arnold DM. Piecing together the humoral and cellular mechanisms of immune thrombocytopenia. Semin Thromb Hemost 2011;37:631–639.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.